Investment Thesis
Cadrenal Therapeutics is a pre-revenue clinical-stage pharmaceutical company with severe negative fundamentals and rapidly depleting cash resources. The company is burning approximately $10M annually with no revenue generation and only ~13 months of cash runway remaining, making near-term capital raise or partnership critical for survival.
Strengths
- Adequate short-term liquidity with $3.9M cash representing 95% of total assets
- Low debt burden with zero long-term debt and minimal leverage
- Maintains current ratio of 3.02x, indicating ability to cover short-term obligations
Risks
- Zero revenue with no clear commercialization timeline for pipeline assets
- Negative operating cash flow of -$10.0M annually indicates unsustainable burn rate
- Severely negative ROE (-372.9%) and ROA (-249.5%) reflect value destruction
- Cash runway of approximately 13 months at current burn rate creates existential liquidity risk
- EPS of -$5.23 on minimal equity base demonstrates pre-commercial stage weakness
- Single Form 4 insider filing in last 90 days suggests minimal insider investment confidence
Key Metrics to Watch
- Operating cash flow trend and monthly burn rate trajectory
- Time-to-cash-depletion and capital raise announcements
- Clinical trial progress, regulatory approvals, and partnership developments
- Cash balance changes and dilution from future financing activities
- Any revenue generation milestones or commercialization progress
Financial Metrics
Revenue
N/A
Net Income
-10.2M
EPS (Diluted)
$-5.23
Free Cash Flow
-10.0M
Total Assets
4.1M
Cash
3.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-372.9%
ROA
-249.5%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
3.02x
Quick Ratio
3.02x
Debt/Equity
0.00x
Debt/Assets
33.1%
Interest Coverage
-2,941.73x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-23T06:20:13.297230 |
Data as of: 2025-09-30 |
Powered by Claude AI